ID: ALA5282974

Max Phase: Preclinical

Molecular Formula: C10H7NO2S

Molecular Weight: 205.24

Associated Items:

Representations

Canonical SMILES:  O=C(O)c1c[nH]c2ccccc2c1=S

Standard InChI:  InChI=1S/C10H7NO2S/c12-10(13)7-5-11-8-4-2-1-3-6(8)9(7)14/h1-5H,(H,11,14)(H,12,13)

Standard InChI Key:  QXIOAYSRXMTILZ-UHFFFAOYSA-N

Associated Targets(Human)

Matrix metalloproteinase 12 1130 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 205.24Molecular Weight (Monoisotopic): 205.0197AlogP: 2.60#Rotatable Bonds: 1
Polar Surface Area: 53.09Molecular Species: ACIDHBA: 2HBD: 2
#RO5 Violations: 0HBA (Lipinski): 3HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: 6.39CX Basic pKa: CX LogP: 1.78CX LogD: 0.73
Aromatic Rings: 2Heavy Atoms: 14QED Weighted: 0.70Np Likeness Score: -0.25

References

1. Arshad JZ, Hanif M..  (2022)  Hydroxypyrone derivatives in drug discovery: from chelation therapy to rational design of metalloenzyme inhibitors.,  13  (10.0): [PMID:36325396] [10.1039/d2md00175f]

Source